Enlivex Ltd. files 20-F

Enlivex Ltd. reported a net income of $1.236 billion for the fiscal year ended December 31, 2025, primarily driven by a $1.631 billion aggregate unrealized, non-cash gain from increases in the fair value of its digital asset treasury and a related derivative asset. The company continues to operate a dual strategy combining clinical development in longevity therapeutics, focused on osteoarthritis, with a treasury model anchored in decentralized prediction markets infrastructure through the RAIN protocol.